Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural tPA and Dornase Alfa for Malignant Pleural Effusions
NCT02135588Phase 1Unknown
- Sponsor
- City of Hope Philadelphia
- Start
- Oct 2013
- Primary completion
- Dec 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tissue-plasminogen activator and dornase alfa in malignant pleural effusion (MPE), sponsored by City of Hope Philadelphia. Primary endpoint: Radiographic improvement in area of pleural collection at Day 14. Status: unknown.
02
Drugs
tissue-plasminogen activatordornase alfa
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT02135588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135588.